Windtree Therapeutics Inc (WINT)
0.5093
0.00 (0.00%)
USD |
NASDAQ |
Nov 21, 16:00
0.5091
0.00 (0.00%)
Pre-Market: 09:03
Windtree Therapeutics Gross Profit Margin (Quarterly)
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2015 | -386.4% |
| December 31, 2014 | 23.82% |
| September 30, 2014 | 51.23% |
| June 30, 2014 | 33.12% |
| March 31, 2014 | -2.42K% |
| December 31, 2013 | -608.2% |
| September 30, 2013 | |
| June 30, 2013 | |
| March 31, 2013 | |
| December 31, 2012 | |
| September 30, 2012 | |
| June 30, 2012 | |
| March 31, 2012 | |
| December 31, 2011 | |
| September 30, 2011 | |
| June 30, 2011 | |
| March 31, 2011 | |
| December 31, 2010 | |
| September 30, 2010 | |
| June 30, 2010 | |
| March 31, 2010 | |
| December 31, 2009 | |
| September 30, 2009 | |
| June 30, 2009 | |
| March 31, 2009 |
| Date | Value |
|---|---|
| December 31, 2008 | |
| September 30, 2008 | |
| June 30, 2008 | |
| March 31, 2008 | |
| December 31, 2007 | |
| September 30, 2007 | |
| June 30, 2007 | |
| March 31, 2007 | |
| December 31, 2006 | |
| September 30, 2006 | |
| June 30, 2006 | |
| March 31, 2006 | |
| December 31, 2005 | |
| September 30, 2005 | |
| June 30, 2005 | |
| March 31, 2005 | |
| December 31, 2004 | |
| September 30, 2004 | |
| June 30, 2004 | |
| March 31, 2004 | |
| December 31, 2003 | |
| September 30, 2003 | |
| June 30, 2003 | |
| March 31, 2003 | |
| December 31, 2002 |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| ANI Pharmaceuticals Inc | 57.48% |
| AIM ImmunoTech Inc | 77.14% |
| Perspective Therapeutics Inc | -- |
| Protalix BioTherapeutics Inc | 53.37% |
| Armata Pharmaceuticals Inc | -- |